source
- Regeneron signs up to $125 million deal with Parabilis to target difficult drug targetsRegeneron announced a deal with Parabilis Medicines valued up to $2.2 billion, with an upfront payment of $125 million. The agreement aims to give Regeneron access to Parabilis’s platform that dis…
- Regeneron's LAG-3 inhibitor fianlimab fails Phase 3 skin cancer trialRegeneron announced that its experimental LAG-3 inhibitor fianlimab did not meet its primary endpoint in a late-stage trial for a skin cancer indication. The Phase 3 study was designed to evaluate…